Thomas Busch has taken over as Chairman of the Board at Swedish biotech company Hiloprobe AB at what he calls “an exciting time” for the thriving business. “We are now ready to transition from a research company to actively marketing and selling our ColoNode biomarker...

Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode's benefits and usefulness in colon cancer. “The results look...

We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries. For more information please read Biocartis...

HiloProbe has participated in a major international surgeon congress in Dublin. - Surgeons are one of our main stakeholders and therefore it important to meet, discuss and present data to them, says Lina Olsson, CEO. HiloProbe participated at the well-attended ESCP...

HiloProbe has CE-marked the ColoNode to satisfy the needs of potential customers who want to start testing the product. - Research Use Only was not enough. Therefore, we have put a lot of focus and resources into completing CE documentation according to IVDD in order...

Den 6 oktober deltog Hiloprobe på Cancerdagen. Här kan du se hela föreläsningen. Det var Marie-Louise Hammarström, professor vid institutionen för klinisk mikrobiologi, Umeå universitet, som på Cancerdagen talade om ett nytt lymfkörteltest för stadieindelning och...

Hiloprobe deltar på Cancerdagen den 6 oktober för att presentera de nya möjligheter som deras diagnostik-kit Colonode kan ge för behandling av kolorektalcancer. Marie-Louise Hammarström, professor vid institutionen för klinisk mikrobiologi, Umeå universitet, ska tala...

HiloProbe has been granted SEK 2 million from Swedish Innovation Agency Vinnova to validate a product that detects and helps treat people with colorectal cancer. “This is an important grant for us and means we can validate our product and make it available to the...

The ColoNode product is now available for research use only! Please, read more about ColoNode at www.colonode.se or click on ColoNode above. Contact us if you are interested to discuss more about ColoNode.

Umeåbolaget HiloProbe har tagit fram en diagnostisk och prognostisk produkt för tjock- och ändtarmscancer. Nu tar man in miljonbelopp i en ny investerarrunda. – Kapitalet är avgörande för att vår produkt ska kunna nå patienterna och komma dem till nytta, säger Lina...